GLP-1 receptor agonists demonstrate clinically meaningful efficacy and safety in pediatric obesity, with liraglutide and semaglutide approved for adolescents.
Background
The global prevalence of pediatric obesity is dramatically rising, leading to increased comorbidities and a significant public health challenge. Traditional lifestyle interventions often fall short in achieving sustained weight management for many children and adolescents. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), which activate the GLP-1R to improve glucose homeostasis and reduce appetite, have revolutionized adult obesity treatment. This review explores their emerging role in pediatric populations, addressing the urgent need for effective pharmacological interventions beyond current standards of care.
Study Design
This narrative review synthesized current evidence on GLP-1 receptor agonists (GLP-1RAs) for weight management in pediatric populations. It evaluated the efficacy, safety, and practical considerations of these agents, specifically highlighting data for liraglutide and injectable semaglutide. The review also considered the role of GLP-1RAs in cardiometabolic effects and kidney function, alongside psychosocial dimensions, economic barriers, and the integration of pharmacotherapy with intensive lifestyle interventions and bariatric surgery.
Results
GLP-1RAs, specifically liraglutide and semaglutide, have demonstrated clinically meaningful efficacy in adolescents with obesity, leading to FDA and EMA approvals for patients ≥12 years. Beyond weight loss, these agents contribute to improved cardiometabolic effects and kidney function. Safety profiles most frequently highlight gastrointestinal adverse events, such as nausea and vomiting, which are generally transient. Importantly, current evidence shows > no consistent impact on growth or pubertal development has been reported to date, addressing a critical concern in pediatric pharmacotherapy. The review also notes preliminary studies suggesting complementary roles for GLP-1RAs alongside metabolic bariatric surgery in selected high-risk patients. However, psychosocial dimensions, including stigma, mental health risks, and potential disordered eating, alongside economic barriers and disparities in access, require careful consideration and efforts to be overcome for equitable implementation.
Key Findings
- Liraglutide and semaglutide demonstrate clinically meaningful efficacy in adolescents with obesity.
- GLP-1RAs are FDA and EMA approved for pediatric patients ≥12 years.
- Most frequent adverse events are gastrointestinal, with no consistent impact on growth or pubertal development.
- GLP-1RAs improve cardiometabolic effects and kidney function in pediatric obesity.
- Psychosocial dimensions, economic barriers, and access disparities require careful consideration.
Why It Matters
For clinicians and parents, the approval of liraglutide and semaglutide offers new, effective pharmacological tools for managing pediatric obesity in adolescents ≥12 years, where options have historically been limited. Integrating GLP-1RAs into a comprehensive, family-centered care model alongside intensive lifestyle interventions (nutritional education, physical activity, behavioral strategies) is crucial for long-term success. This suggests that while these peptides are powerful, they are not a standalone solution. Future protocols might involve combined approaches with bariatric surgery for high-risk patients. However, the need to address psychosocial factors and economic disparities remains paramount to ensure equitable access and optimal patient outcomes, moving beyond just the pharmacological effect.
pediatric obesity
glp-1ra
liraglutide
semaglutide
adolescent obesity
weight management